Top

Current Treatment Options in Gastroenterology

Published in:

13-07-2023 | Eosinophilic Esophagitis

Emerging Medical Therapy in Eosinophilic Esophagitis

Authors: Jessica Stout, DO, Kathryn Peterson, MD, MS

Published in: Current Treatment Options in Gastroenterology | Issue 3/2023

Abstract

Purpose of review

In decades prior, eosinophilic esophagitis was considered a rare diagnosis. For reasons that cannot be fully explained by an increase in disease recognition alone, eosinophilic esophagitis is rising in incidence and prevalence. This article will highlight the most up-to date literature for emerging medical therapy for this disease.

Recent findings

It is estimated that nearly one-third of patients with eosinophilic esophagitis will not respond to traditional pharmacologic therapies which include proton-pump inhibitors and swallowed topical corticosteroids. The need for more effective therapy has led to an explosion of research for targeted biologic therapies, and there are several promising molecules in the pipeline.

Summary

A number of Phase II and III clinical trials are underway and show propitious results for treatment in eosinophilic esophagitis. In 2022, the Food and Drug Administration approved the first treatment for eosinophilic esophagitis, dupilumab. This approval satisfies an unmet need for a growing number of patients with eosinophilic esophagitis. It is likely that in the future, there will be multiple therapeutic options for the management of eosinophilic esophagitis.

Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154(2):319-332.e3. https://doi.org/10.1053/j.gastro.2017.06.067.CrossRefPubMed

Uppal V, Kreiger P, Kutsch E. Eosinophilic gastroenteritis and colitis: a comprehensive review. Clinic Rev Allerg Immunol. 2016;50:175–88. https://doi.org/10.1007/s12016-015-8489-4.CrossRef

O’Shea KM, Aceves SS, Dellon ES, Gupta SK, Spergel JM, Furuta GT, Rothenberg ME. Pathophysiology of eosinophilic esophagitis. Gastroenterology. 2018;154(2):333–45. https://doi.org/10.1053/j.gastro.2017.06.065.CrossRefPubMed

Hui CC, Rusta-Sallehy S, Asher I, Heroux D, Denburg JA. The effects of thymic stromal lymphopoietin and IL-3 on human eosinophil-basophil lineage commitment: relevance to atopic sensitization. Immun Inflamm Dis. 2014;2(1):44–55. https://doi.org/10.1002/iid3.20.CrossRefPubMedPubMedCentral

Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med. 2018;5:49. https://doi.org/10.3389/fmed.2018.00049.CrossRef

Avlas S, Shany G, Rhone N, Dolitzky A, Hazut I, Grisaru-Tal S, Itan M, Varol C, Ballaban A, Rochman M, Diesendruck Y, Nahary L, Bitton A, Benhar I, Rothenberg M, Munitz A. Eosinophilic esophagitis is critically mediated by IL-13 signaling via IL13Ra1. Journal of Allergy and Clinical Immunology, Volume 149, Issue 2, Supplement, 2022, Page AB52, ISSN 0091–6749, https://doi.org/10.1016/j.jaci.2021.12.203.

Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW. Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res. 2001;2(2):71–9. https://doi.org/10.1186/rr41.CrossRefPubMedPubMedCentral

Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116:536–47.CrossRefPubMedPubMedCentral

Zhernov YV, Vysochanskaya SO, Sukhov VA, Zaostrovtseva OK, Gorshenin DS, Sidorova EA, Mitrokhin OV. Molecular mechanisms of eosinophilic esophagitis. Int J Mol Sci. 2021;22(24):13183. https://doi.org/10.3390/ijms222413183.CrossRefPubMedPubMedCentral

10.

Bolton SM, Kagalwalla AF, Arva NC, Wang MY, Amsden K, Melin-Aldana H, Dellon ES, Bryce PJ, Wershil BK, Wechsler JB. Mast cell infiltration is associated with persistent symptoms and endoscopic abnormalities despite resolution of eosinophilia in pediatric eosinophilic esophagitis. Am J Gastroenterol. 2020;115(2):224–33. https://doi.org/10.14309/ajg.0000000000000474.CrossRefPubMedPubMedCentral

11.

Davis BP, Rothenberg ME. Mechanisms of disease of eosinophilic esophagitis. Annu Rev Pathol. 2016;23(11):365–93. https://doi.org/10.1146/annurev-pathol-012615-044241.CrossRef

12.

Muir AB, Wang JX, Nakagawa H. Epithelial-stromal crosstalk and fibrosis in eosinophilic esophagitis. J Gastroenterol. 2019;54:10–8. https://doi.org/10.1007/s00535-018-1498-3.CrossRefPubMed

13.

Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther. 2012;135(3):327–36. https://doi.org/10.1016/j.pharmthera.2012.06.005.CrossRefPubMedPubMedCentral

14.

Bochner BS. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy. 2009;39(3):317–24. https://doi.org/10.1111/j.1365-2222.2008.03173.x.CrossRefPubMedPubMedCentral

15.

Racca F, Pellegatta G, Cataldo G, Vespa E, Carlani E, Pelaia C, Paoletti G, Messina MR, Nappi E, Canonica GW, Repici A, Heffler E. Type 2 inflammation in eosinophilic esophagitis: from pathophysiology to therapeutic targets. Front Physiol. 2022;12:815842. https://doi.org/10.3389/fphys.2021.815842.CrossRefPubMedPubMedCentral

16.

Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, KubalaHavrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18(11):1021–33. https://doi.org/10.1016/S1474-4422(19)30238-8.CrossRefPubMed

17.

Wen T, Aronow BJ, Rochman Y, Rochman M, Kc K, Dexheimer PJ, Putnam P, Mukkada V, Foote H, Rehn K, Darko S, Douek D, Rothenberg ME. Single-cell RNA sequencing identifies inflammatory tissue T cells in eosinophilic esophagitis. J Clin Invest. 2019;129(5):2014–28. https://doi.org/10.1172/JCI125917.CrossRefPubMedPubMedCentral

18.

Venkateshaiah SU, Kandikattu HK, Yadavalli CS, Mishra A. Eosinophils and T cell surface molecule transcript levels in the blood differentiate eosinophilic esophagitis (EoE) from GERD. Int J Basic Clin Immunol. 2021;4(1–2):1–8.PubMedPubMedCentral

19.

Morgan DM, Ruiter B, Smith NP, Tu AA, Monian B, Stone BE, Virk-Hundal N, Yuan Q, Shreffler WG, Love JC. Clonally expanded, GPR15-expressing pathogenic effector TH2 cells are associated with eosinophilic esophagitis. Sci Immunol. 2021;6(62):eabi5586. https://doi.org/10.1126/sciimmunol.abi5586.CrossRefPubMedPubMedCentral

20.

Manresa MC, Chiang AWT, Kurten RC, Dohil R, Brickner H, Dohil L, Herro R, Akuthota P, Lewis NE, Croft M, Aceves SS. Increased production of light by T cells in eosinophilic esophagitis promotes differentiation of esophageal fibroblasts toward an inflammatory phenotype. Gastroenterology. 2020;159(5):1778-1792.e13. https://doi.org/10.1053/j.gastro.2020.07.035.CrossRefPubMed

21.

Molina-Infante J, Ferrando-Lamana L, Ripoll C, Hernandez-Alonso M, Mateos JM, Fernandez-Bermejo M, Dueñas C, Fernandez-Gonzalez N, Quintana EM, Gonzalez-Nuñez MA. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol. 2011;9(2):110–7. https://doi.org/10.1016/j.cgh.2010.09.019.CrossRefPubMed

22.

Molina-Infante J, Bredenoord AJ, Cheng E, Dellon ES, Furuta GT, Gupta SK, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65:524–31. https://doi.org/10.1136/gutjnl-2015-310991.CrossRefPubMed

23.

Hirano I, Chan ES, Rank MA, Sharaf RN, Stollman NH, Stukus DR, Wang K, Greenhawt M, Falck-Ytter YT. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158(6):1776–86. https://doi.org/10.1053/j.gastro.2020.02.038.CrossRefPubMed

24.

van Rhijn BD, Weijenborg PW, Verheij J, van den Bergh Weerman MA, Verseijden C, van den Wijngaard RM, de Jonge WJ, Smout AJ, Bredenoord AJ. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014;12(11):1815-23.e2. https://doi.org/10.1016/j.cgh.2014.02.037.CrossRefPubMed

25.

Caviglia R, Ribolsi M, Maggiano N, Gabbrielli AM, Emerenziani S, Guarino MP, Carotti S, Habib FI, Rabitti C, Cicala M. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol. 2005;100(3):543–8. https://doi.org/10.1111/j.1572-0241.2005.40978.x.CrossRefPubMed

26.

Feo-Ortega S, Lucendo AJ. Evidence-based treatments for eosinophilic esophagitis: insights for the clinician. Therap Adv Gastroenterol. 2022;19(15):17562848211068664. https://doi.org/10.1177/17562848211068665.CrossRef

27.

Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, Jameson SC, Kirby C, Konikoff MR, Collins MH, Cohen MB, Akers R, Hogan SP, Assa’ad AH, Putnam PE, Aronow BJ, Rothenberg ME. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116(2):536–47. https://doi.org/10.1172/JCI26679.CrossRefPubMedPubMedCentral

28.

Rank MA, Sharaf RN, Furuta GT, et al. Technical review on the management of eosinophilic esophagitis: a report from the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. Gastroenterology. 2020;158:1789–810.CrossRefPubMed

29.

Lucendo AJ, Miehlke S, Schlag C, Vieth M, von Arnim U, Molina-Infante J, Hartmann D, Bredenoord AJ, de Los Ciriza, Rios C, Schubert S, Brückner S, Madisch A, Hayat J, Tack J, Attwood S, Mueller R, Greinwald R, Schoepfer A, Straumann A, International EOS-1 study group. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157(1):74-86.e15. https://doi.org/10.1053/j.gastro.2019.03.025.CrossRefPubMed

30.

Straumann A, Lucendo AJ, Miehlke S, Schoepfer A, Attwood S, et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology 159(5):1672-1685

31.

• Miehlke S, Lucendo AJ, Straumann A, Jan Bredenoord A, Attwood S. Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence. Therap Adv Gastroenterol. 2020;10(13):1756284820927282. https://doi.org/10.1177/1756284820927282. Convenience and consistency in formulation of topical steroids leads to more effective disease control.CrossRef

32.

Greuter T, Safroneeva E, Bussmann C, Biedermann L, Vavricka SR, Katzka DA, Schoepfer AM, Straumann A. Maintenance treatment of eosinophilic esophagitis with swallowed topical steroids alters disease course over a 5-year follow-up period in adult patients. Clin Gastroenterol Hepatol. 2019;17(3):419-428.e6. https://doi.org/10.1016/j.cgh.2018.05.045.CrossRefPubMed

33.

Mishra A, Hogan SP, Brandt EB, Rothenberg ME. IL-5 promotes eosinophil trafficking to the esophagus. J Immunol. 2002;168(5):2464–9. https://doi.org/10.4049/jimmunol.168.5.2464.CrossRefPubMed

34.

Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des Devel Ther. 2017;30(11):3137–44. https://doi.org/10.2147/DDDT.S150656.CrossRef

35.

Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, Terracciano R, Pelaia G. Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. Biomed Res Int. 2018;10(2018):4839230. https://doi.org/10.1155/2018/4839230.CrossRef

36.

Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, Filipovich AH, Assa’ad AH, Rothenberg ME. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2006;118(6):1312–9. https://doi.org/10.1016/j.jaci.2006.09.007.CrossRefPubMed

37.

Rothenberg, ME. A multicenter, randomized, double-blind, parallel-group, placebo controlled study to investigate the use of benralizumab for eosinophilic esophagitis (MESSINA). ClinicalTrials.gov identifier: NCT04543409. Updated October 7, 2022.Accessed October 11, 2022. https://clinicaltrials.gov/ct2/show/NCT04543409.

38.

“Update on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis.” AztraZeneca.com. October 25, 2022. https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-messina-phase-iii-trial.html.

39.

Novel Drug Approvals for 2015. U.S. Food & Drug Administration. November 4, 2015. Accessed October 11, 2022. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2015

40.

Novel Drug Approvals for 2017. U.S. Food & Drug Administration. November 14, 2017. Accessed October 11, 2022. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017

41.

FDA approves first treatment for eosinophilic esophagitis, a chronic immune disorder. May 20, 2022. Accessed October 12, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-eosinophilic-esophagitis-chronic-immune-disorder

42.

Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–37. https://doi.org/10.1080/1744666X.2017.1298443.CrossRefPubMed

43.

Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158:111-122.e10.CrossRefPubMed

44.

Dellon ES, Rothenberg ME, Collins MH, Hirano I, Chehade M, Bredenoord AJ, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Eng J Med 2022;387(25):2317–2330. https://doi.org/10.1056/NEJMoa2205982.

45.

Dellon ES, et al. A Phase 3, Randomized, 3-part study to investigate the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis: results from part A. American College of Gastroenterology Meeting: Oral Paper Presentation. October 26, 2020.

46.

Hirano I, Collins MH, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer AM, et al. RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology 2019;156(3):592–603.e10, ISSN 0016–5085. https://doi.org/10.1053/j.gastro.2018.10.051.

47.

Dellon ES, Collins MH, Rothenberg ME, Assouline-Dayan Y, Evans L, Gupta S, et al. Long term efficacy and tolerability of RPC4046 in an open-label extension trial of patients with eosinophilic esophagitis. Gastroenterology. 2019;156:592-603.e10.PubMed

48.

Youngblood BA, Brock EC, Leung J, Falahati R, Bochner BS, Rasmussen HS, et al. Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic esophagitis. JCI Insight. 2019;4:e126219.CrossRefPubMedPubMedCentral

49.

Dellon ES, Peterson KA, Murray JA, et al. Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis. N Engl J Med. 2020;383(17):1624–34.CrossRefPubMedPubMedCentral

50.

Allakos. Allakos announces topline phase 3 data from the ENIGMA 2 study and phase 2/3 data from the KRYPTOS study in patients with eosinophilic gastrointestinal diseases. https://investor.allakos.com/news-releases/news-release-details/allakos-announces-topline-phase-3-data-enigma-2-study-and-phase. Published December 21, 2021. Accessed November 7, 2022.

51.

•• Peterson K, Safroneeva E, Schoepfer A. Emerging therapies for eosinophilic gastrointestinal diseases. J Allergy Clin Immunol Pract. 2021;9(9):3276–81. https://doi.org/10.1016/j.jaip.2021.07.031. More literature is emerging to suggest that eradication of eosinophils does not equal resolution of dysphagia. There is more to the story, which we hope future research will clarify.CrossRefPubMed

52.

Marsolais D, Yagi S, Kago T, Leaf N, Rosen H. Modulation of chemokines and allergic airway inflammation by selective local sphingosine-1-phosphate receptor 1 agonism in lungs. Mol Pharmacol. 2011;79(1):61–8. https://doi.org/10.1124/mol.110.066811.CrossRefPubMedPubMedCentral

53.

Arena Pharmaceuticals announces Orphan Drug designation for etrasimod for the treatment of eosinophilic esophagitis (EoE). [press release]. Park City, Utah: Arena Pharmaceuticals, Inc.; June 9, 2021.

54.

Man F, Nadkarni S, Kanabar V, e-Lacerda RR, Ferreira SG, Canova DF, Perretti M, Page CP, Riffo-Vasquez Y. A peptide derived from chaperonin 60.1, IRL201104, inhibits LPS-induced acute lung inflammation. Am J Physiol-Lung Cell Mol Physiol. 2021;321(5):L803–13.CrossRefPubMed

55.

Lewthwaite JC, Coates AR, Tormay P, Singh M, Mascagni P, Poole S, Roberts M, Sharp L, Henderson B. Mycobacterium tuberculosis chaperonin 60.1 is a more potent cytokine stimulator than chaperonin 60.2 (Hsp 65) and contains a CD14-binding domain. Infect Immun. 2001;69(12):7349–55. https://doi.org/10.1128/IAI.69.12.7349-7355.2001.CrossRefPubMedPubMedCentral

56.

Riffo-Vasquez Y, Kanabar V, Keir SD, e-Lacerda RR, Man F, Jackson DJ, Corrigall V, Coates ARM, Page CP. Modulation of allergic inflammation in the lung by a peptide derived from Mycobacteria tuberculosis chaperonin 60.1. Clin Exp Allergy. 2020;50:508–19. https://doi.org/10.1111/cea.13550.CrossRefPubMed

57.

Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis. https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html. Published October 8, 2021. Accessed November 9, 2022.

58.

Lam AY, Ma C, Lee JK, Bredenoord AJ. Eosinophilic esophagitis: new molecules, better life?. Curr Opin Pharmacol. 2022;63 102183, ISSN 1471–4892.

Title: Emerging Medical Therapy in Eosinophilic Esophagitis
Authors: Jessica Stout, DO
Kathryn Peterson, MD, MS
Publication date: 13-07-2023
Publisher: Springer US
Keywords: Eosinophilic Esophagitis
Dupilumab
Dysphagia
Dysphagia
Mepolizumab
Eosinophilia
Dysphagia
Published in: Current Treatment Options in Gastroenterology / Issue 3/2023
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-023-00425-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2023

Diagnosis and Treatment of Refractory GERD

Artificial Intelligence in Colorectal Cancer Screening

Management of Esophageal Squamous Cell Neoplasia

Evolving Role of Endoscopic Submucosal Dissection in the Management of Barrett’s Neoplasia

Barrett’s Esophagus: When to Scope and When to Ablate

How to Improve the Efficacy of Gastric Cancer Screening?

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage